Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
33%
Ph phase_1
2
67%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (66.7%)
Phase 21 (33.3%)

Trials by Status

completed3100%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_2

Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma

NCT02117258
completedphase_1

A Healthy Subject Study With Z-360 and Placebo

NCT01776463
completedphase_1

Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment

NCT00288925

Clinical Trials (3)

Showing 3 of 3 trials
NCT02117258Phase 2

Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma

Completed
NCT01776463Phase 1

A Healthy Subject Study With Z-360 and Placebo

Completed
NCT00288925Phase 1

Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3